BNR

Burning Rock Biotech

16.62 USD
+0.61
3.81%
At close Updated Mar 16, 3:54 PM EDT
1 day
3.81%
5 days
-26.07%
1 month
-43.76%
3 months
-11.31%
6 months
95.76%
Year to date
-15.55%
1 year
186.55%
5 years
-93.57%
10 years
-93.25%
 

About: Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Employees: 674

0
Funds holding %
of 8,079 funds
Analysts bullish %
Positive news %
Price charts implemented using Lightweight Charts™